PRTA
NASDAQ · Biotechnology
Prothena Corp Plc
$8.93
+0.44 (+5.18%)
Financial Highlights (FY 2026)
Revenue
10.19M
Net Income
-256,968,598
Gross Margin
—
Profit Margin
-2,520.6%
Rev Growth
-43.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 66.9% | 66.9% |
| Operating Margin | -2,216.4% | -1,994.8% | -17.7% | -18.1% |
| Profit Margin | -2,520.6% | -2,394.5% | -16.3% | -12.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 10.19M | 18.07M | 162.70M | 132.11M |
| Gross Profit | — | — | 108.91M | 88.43M |
| Operating Income | -225,958,233 | -360,379,956 | -28,741,203 | -23,889,033 |
| Net Income | -256,968,598 | -409,838,274 | -26,550,677 | -16,869,914 |
| Gross Margin | — | — | 66.9% | 66.9% |
| Operating Margin | -2,216.4% | -1,994.8% | -17.7% | -18.1% |
| Profit Margin | -2,520.6% | -2,394.5% | -16.3% | -12.8% |
| Rev Growth | -43.6% | -43.6% | +13.5% | +18.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 103.68M | 102.66M |
| Total Equity | — | — | 280.84M | 243.54M |
| D/E Ratio | — | — | 0.37 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -225,018,945 | -378,819,772 | -39,466,979 | -33,822,388 |
| Free Cash Flow | — | — | -19,760,246 | -19,201,664 |